ライフサイエンスコーパス: betaglycan

1 ta) receptor (TbetaRIII, also referred to as betaglycan).

2 ociation with the transmembrane proteoglycan betaglycan.

3 pe III TGF-beta receptor Tgfbr3, also called betaglycan.

4 domain as the only inhibin-binding region in betaglycan.

5 tors, and this competition is facilitated by betaglycan.

6 hich does not bind inhibin in the absence of betaglycan.

7 on of the glycosaminoglycan modifications of betaglycan.

8 pithelial LLC-PK1 cells that lack endogenous betaglycan.

9 es binding in cells co-expressing ActRII and betaglycan.

10 he type III TGF-beta receptor (TbetaRIII, or betaglycan), a ubiquitously expressed TGF-beta corecepto

11 ral human and animal diseases, although both betaglycan actions and the ligands involved in these dis

12 Betaglycan also enables inhibin to bind to and compete w

13 viously that ectopic expression of a soluble betaglycan, also known as transforming growth factor (TG

14 oglin has homology to the type III receptor, betaglycan, although its exact role in TGF-beta signalin

15 both recombinant and endogenously expressed betaglycan and ActRII.

16 es identify a novel, dual role for TbetaRIII/betaglycan and define a key requirement for the balance

17 Nonpolymerizing ZP proteins such as betaglycan and endoglin do not contain this cleavage sit

18 Other ZP proteins (namely, betaglycan and endoglin) do not polymerize but serve as

19 Recently, betaglycan and inhibin binding protein (InhBP/p120, also

20 Betaglycan binds inhibin with high affinity and enhances

21 The type III receptor, also known as betaglycan, binds to the type II receptor and is thought

22 an-2 specifically co-immunoprecipitated with betaglycan but not with TbetaRI or TbetaRII.

23 Betaglycan can confer inhibin responsiveness on cells th

24 Our data indicate that betaglycan can function as a potent inhibitor of TGF-bet

25 Inhibin, in concert with its co-receptor, betaglycan, can compete with activin for binding to type

26 ngs demonstrate that inhibin, acting through betaglycan, can function as an antagonist of BMP respons

27 we show that the type III TGF-beta receptor, betaglycan, can function as an inhibin co-receptor with

28 Finally, betaglycan confers inhibin sensitivity to cell lines tha

29 ssion of the metastasis suppressor TbetaRIII/betaglycan decreases invasiveness.

30 Inhibiting either signaling or betaglycan expression attenuated differentiation.

31 for the first time, epigenetic regulation of betaglycan expression in ovarian cancer, and a novel rol

32 Although restoring betaglycan expression in Ovca429 ovarian cancer cells is

33 Here, we show that betaglycan expression is frequently decreased or lost in

34 tic silencing may play a role in the loss of betaglycan expression observed in ovarian cancer.

35 Loss of betaglycan expression, or abrogation of betaglycan funct

36 hat type III TGF-beta receptor (TbetaRIII or betaglycan) expression is decreased or lost in the major

37 a domain spanning amino acids 591-700 of the betaglycan extracellular domain as the only inhibin-bind

38 orming growth factor-beta type III receptor, betaglycan, fails to interact with zyxin.

39 luble TGF-beta type III receptor (TbetaRIII; betaglycan)-Fc reconstituted a soluble high affinity inh

40 We now show that the betaglycan form of TbetaRIII is highly modified followin

41 s of betaglycan expression, or abrogation of betaglycan function, is implicated in several human and

42 will allow the clarification of the role of betaglycan in disease states such as renal cell carcinom

43 In comparison, the expression of betaglycan in L6 myoblasts enhances TGF-beta signaling,

44 The effects of betaglycan in LLC-PK1 cells are not mediated by ligand s

45 Betaglycan in LLC-PK1 cells exhibits higher molecular we

46 We demonstrate that the expression of betaglycan in LLC-PK1 cells results in inhibition of TGF

47 sion in ovarian cancer, and a novel role for betaglycan in regulating ovarian cancer motility and inv

48 We have examined the function of betaglycan in renal epithelial LLC-PK1 cells that lack e

49 s, suggesting a broader role for inhibin and betaglycan in restricting and refining a wide spectrum o

50 Betaglycan increases the affinity of inhibins for the ac

51 Betaglycan is a co-receptor that mediates signaling by t

52 genetic and biochemical evidence showed that betaglycan is not a substrate of the shedding system.

53 wth factor beta type III receptor (TbetaRIII/betaglycan) is a transmembrane proteoglycan co-receptor

54 The TGF-beta type III receptor (TbetaRIII or betaglycan) is an abundant cell surface proteoglycan tha

55 GF-beta) receptor (TbetaRIII), also known as betaglycan, is the most abundantly expressed TGF-beta re

56 lted in significant synergistic induction of betaglycan message levels and increased betaglycan prote

57 an (GAG) chains than in L6 cells, and a GAG- betaglycan mutant does not inhibit TGF-beta signaling or

58 These betaglycan mutants fail to mediate inhibin antagonism of

59 the type III TGF-beta receptor (TbetaRIII or betaglycan), occurs in a broad spectrum of human cancers

60 Betaglycan, or the type III TGF-beta receptor, is a core

61 LC-PK1 cells, unlike L6 cells, expression of betaglycan prevents association between the type I and t

62 n of betaglycan message levels and increased betaglycan protein expression, indicating that epigeneti

63 mbinant preparation of human and rat soluble betaglycan (sBG).

64 he type III TGF-beta receptor (TbetaRIII, or betaglycan) serves as a novel suppressor of cancer progr

65 A third cell surface receptor, betaglycan, serves as a co-receptor for TGF-beta in some

66 F-beta-mediated inhibition of proliferation, betaglycan significantly inhibits ovarian cancer cell mo

67 se we chose the TGF-beta accessory receptor, betaglycan, since genetic and biochemical evidence showe

68 Furthermore, betaglycan specifically enhances the antimigratory effec

69 ng regions of TGF-alpha or beta-APP rendered betaglycan susceptible to ectodomain shedding.

70 red to as the type I, type II, and type III (betaglycan) TGF-beta receptors.

71 The ability of betaglycan to facilitate inhibin antagonism of activin p

72 rodimer, in conjunction with the co-receptor betaglycan, to block activin receptor-ligand binding, co

73 Separating the co-receptor actions of betaglycan toward inhibin and TGFbeta will allow the cla

74 TGF-beta2 appears to require the co-receptor betaglycan (type III receptor, TbetaRIII) for high affin

75 Full-length betaglycan V614Y, and other mutations, retain TGFbeta bi

76 l of type III TGF-beta receptor (TbetaRIII), betaglycan, whereas S2 resulted in a decrease.

77 s I and II receptors with t1/2 of 2 h and to betaglycan with t1/2 of 6 h.

78 cids adjacent to the transmembrane region of betaglycan with the corresponding regions of TGF-alpha o

79 This binding site is within the betaglycan ZP domain, but inhibin binding is not integra

80 he 2.0-A resolution crystal structure of the betaglycan ZP-C region in combination with a downstream